Australia - English - Department of Health (Therapeutic Goods Administration)

Buy It Now

Active ingredient:
borax,bovine sodium chondroitin sulfate,glucosamine sulfate sodium chloride,manganese gluconate
Available from:
Blackmores Ltd
INN (International Name):
bovine sodium chondroitin sulfate,Borax,glucosamine sulfate sodium chloride,Manganese gluconate
Authorization status:
Authorization number:

Read the complete document

Public Summary

Summary for ARTG Entry:



ARTG entry for

Medicine Listed


Blackmores Ltd

Postal Address

PO Box 1725,WARRIEWOOD, NSW, 2102


ARTG Start Date


Product category




Approval area

Listed Medicines


Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in

the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine,

(b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is

sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be


The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records

to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted

in relation to the inclusion of the medicine in the Register.

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office

of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors

of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified

of the report or reports.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine

outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National

Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.



Product Type

Single Medicine Product

Effective date



If symptoms persist consult your healthcare practitioner (or words to that effect).

Standard Indications

Aids, assists or helps in the maintenance of general well-being

Specific Indications

May provide symptomatic relief of osteoarthritis.

May relieve joint pain caused by osteoarthritis.

May increase joint mobility and reduce joint stiffness associated with osteoarthritis.

May protect joint cartilage in osteoarthritis.

Specifically formulated to provide joint nutrition.

Chondroitin sulfate plays an important role in the lubrication and nutrition of the joint.

Helps/aids/assists to stimulate the manufacture of glycosaminoglycans, key structural components of cartilage.

May help/aid/assist to protect cartilage from deterioration/breakdown (by inhibiting enzymes involved in cartilage breakdown).

Manganese is important for the production of cartilage and bone.

Manganese is a component of manganese super oxide dismutase (MnSOD), an antioxidant enzyme which helps to protect cellular components from free

radical damage.

Boron plays a role in the chemical make-up of bones and joints.

Chondroitin sulfate in cartilage resists compressive loads.

Helps maintain / support normal (joint health) / (cartilage health / integrity).

Helps normal / healthy joint function through maintaining cartilage.

May support healthy joint flexibility & mobility.

Additional Product information

Pack Size/Poison information

Pack Size

Poison Schedule


1. Formulation 1

Public Summary

Page 1 of

Produced at 24.11.2017 at 06:40:18 AEDT

This is not an ARTG Certificate document.

The onus is on the reader to verify the current accuracy of the information on the document subsequent to the date shown.

Visit for contact information

Dosage Form

Tablet, film coated

Route of Administration


Visual Identification

Active Ingredients


8.83 mg

bovine sodium chondroitin sulfate

225 mg

glucosamine sulfate sodium chloride

942 mg

Manganese gluconate

8.77 mg

© Commonwealth of Australia.This work is copyright.You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior

written approval from the Commonwealth.Further details can be found at

Public Summary

Page 2 of

Produced at 24.11.2017 at 06:40:18 AEDT

This is not an ARTG Certificate document.

The onus is on the reader to verify the current accuracy of the information on the document subsequent to the date shown.

Visit for contact information

Similar products

Search alerts related to this product

Share this information